Skip to Content
Skip to main content

Dr Sara Anjomani Virmouni
Senior Lecturer in Biomedical Sciences


Sara was educated at the University of Tehran, where she was awarded a Bachelor degree in animal sciences with first class honours in 2008. She moved to the Biosciences Division at Brunel University London to undertake her MSc in Molecular Medicine and Cancer Research. In 2011, Sara was awarded a scholarship by the School of Health Sciences and Social Care, Brunel University London to investigate Friedreich’s ataxia (FRDA) disease mechanisms using FRDA mouse models and cells under the supervision of Dr Mark Pook. She finished her PhD in 2013 and was awarded Vice Chancellor's best doctoral research prize. She continued her work as a Postdoctoral Research Fellow at Brunel University London to study the efficacy and tolerability of histone methyltransferase (HMTase) inhibitors in FRDA. Sara then joined the Institute of Cancer Research (ICR) as a Postdoctoral Research Fellow in 2015 to study the signaling and metabolic networks in breast cancer. In 2018, she was awarded a research grant from Friedreich’s Ataxia Research Alliance (FARA) and joined Brunel University London as a Principal Investigator to investigate the metabolic signatures of FRDA. Subsequently, she was appointed as a lecturer in Biosciences. Her research continues to investigate FRDA disease pathogenesis and therapy and identify the most effective therapy for FRDA.


  • BSc: Animal Sciences, University of Tehran
  • MSc: Molecular Medicine & Cancer Research, Brunel University London
  • PhD: Biomedical Sciences, Brunel University London
  • Postgraduate Certificate in Academic Practice (PgCAP)
  • Fellow of Higher Education Academy (FHEA)


  • BB5705 – Disease Mechanisms and Therapeutics
  • BB5708 – Gene Expression & Epigenetics
  • BB3707 – Cellular Pathologies
  • BB2712 – Principles of Human Disease
  • BB1701 – Module Coordinator - Principles of Anatomy and Physiology
  • BB1703 – Research Skills
  • BB1806 – Assessment Coordinator

Newest selected publications

Edzeamey, FJ., Ramchunder, Z., Pourzand, C. and Anjomani-Virmouni, S. (2024) 'Emerging antioxidant therapies in Friedreich's ataxia'. Frontiers in Pharmacology, 15. pp. 1 - 17.Open Access Link

Journal article

Kalef-Ezra, E., Edzeamey, FJ., Valle, A., Khonsari, H., Kleine, P., Oggianu, C., et al. (2023) 'A new FRDA mouse model [Fxnnull:YG8s(GAA) > 800] with more than 800 GAA repeats'. Frontiers in Neuroscience, 17. pp. 1 - 12. ISSN: 1662-4548 Open Access Link

Journal article

Koundouros, N., Karali, E., Tripp, A., Valle, A., Inglese, P., Perry, NJS., et al. (2020) 'Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids'. Cell, 181 (7). pp. 1596 - 1611. ISSN: 0092-8674 Open Access Link

Journal article

Sherzai, M., Valle, A., Perry, N., Kalef-Ezra, E., Al-Mahdawi, S., Pook, M. and et al. (2020) 'HMTase Inhibitors as a Potential Epigenetic-based Therapeutic Approach for Friedreich’s Ataxia'. Frontiers in Genetics, 11. pp. 1 - 10. ISSN: 1664-8021 Open Access Link

Journal article

Anjomani-Virmouni, S., Kalef-Ezra, E., Valle, A., Perry, N., Tripp, A., Agliano, A., et al. (2019) 'Elucidation of the metabolic signature of Friedreich’s ataxia'.IARC International Ataxia Research Conference. Washington, DC, USA. 14 - 16 November.Open Access Link

Conference paper
More publications(25)